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The immune system and the microbiota mutually interact to maintain homeostasis in the intestine.
However, components of the microbiota can alter this balance and promote chronic inflammation,
promoting intestinal tumor development.We review recent advances in understanding the complex
interactions between themicrobiota and the innate and adaptive immune systems and discuss their
potential to lead us in new directions for understanding cancer biology and treatment.Introduction
As early as the 19th century, Robert Koch and Louis Pasteur had
reported finding bacteria at tumor sites. In 1890, William Russell
reported to the Pathological Society of London the discovery of a
cancer parasite. However, during the first half of the 20th cen-
tury, the theory that bacteria could cause cancer was considered
heresy. Recently, a growing body of evidence has started to
reveal that William Russell was right. Bacteria can drive tumor
growth, and their interaction with the immune system can further
fuel cancer progression. This is especially true at mucosal inter-
faces where bacteria are abundant and the immune system is
highly reactive.
The number of bacteria in the human intestine is estimated to
be around 1 3 1014, outnumbering the eukaryotic cells by a
factor of ten or more. Usually the microbiota does not elicit a
proinflammatory immune response, as coevolution of the host
mucosal immune system and commensal organisms developed
multiple mechanisms for maintaining homeostasis. However,
when these mechanisms are impaired and/or pathogenic bacte-
ria are introduced into this tightly balanced ecosystem, the
immune system responds to the microbiota and can trigger
and/or sustain tumor growth in the intestine.
The reduced incidence of intestinal cancer in germ-free ro-
dents that are geneticallymodified to promote tumor susceptibil-
ity, as compared to animals of the same genotype with normal
microbiota, provides compelling evidence for microbiota’s role
in tumor growth (Reddy et al., 1975; Vannucci et al., 2008). The
bacteria present in the intestine impact tumor development
through multiple signaling pathways, some elicited by secretion
bacterial-derived molecules. Themechanisms by which bacteria
promote tumorigenesis can be direct or indirect (Table 1). As an
example of a direct mechanism, deoxycholic acid (DCA), a gut
bacterial metabolite, can directly cause DNA damage and, in
turn, promote tumor development (Yoshimoto et al., 2013).
In addition, E. coli NC101 can directly cause tumor growth in
the intestine thanks to Colibactin, a peptide-polyketide hybrid776 Cell 157, May 8, 2014 ª2014 Elsevier Inc.genotoxin (Arthur et al., 2012). Finally, Fusobacterium nucleatum
has recently been shown to directly promote intestinal tumori-
genesis when its adhensin, FadA, binds to E-cadherin on epithe-
lial cells and activates b-catenin signaling to promote epithelial
cell proliferation (Rubinstein et al., 2013) (Kostic et al., 2013).
Indirect mechanisms by which bacteria promote tumor growth
involve the chronic activation of the immune system (Figure 1).
In this Review, we will mainly focus on the indirect mechanisms
by which the microbiota can initiate and/or sustain tumor devel-
opment in the intestine through modulation of the innate and
adaptive arms of the immune system.
Innate Immune Receptors, Microbes, and Tumor
Development
The innate immune system is a universal and evolutionarily
conserved arm of the host immune defense system that enables
rapid response to invading pathogens (Medzhitov, 2001). Sig-
naling through pattern recognition receptors (PRRs), which
include, among others, Nod-like receptors (NLRs) and Toll like
receptors (TLRs), enables host immune sensing and reactivity
toward diverse stimuli. Standing at the interface between micro-
biota and the immune system, the PPRs decode signals from the
microbiota and help to shape the homeostatic host-microbiota
interface. When the immune response does not properly control
the microbiota—for example, due to a deficiency in these
sensing platforms—alterations of commensal communities and
emergence of normally suppressed bacteria can cause delete-
rious effects to the host. Throughout the text, we refer to this
type of microflora as altered, or dysbiotic, microbiota. One of
the main effects of dysbiosis is chronic unchecked activation
of the immune system, thereby creating a proinflammatory
milieu, which may favor the development and progression of
neoplastic lesions in the intestine.
Nod-like Receptors
The NLR family is a group of cytosolic receptor proteins that
can be activated by a large variety of both endogenous and
Table 1. Tumors’ Associated Bacteria and Mechanism of Action
Bacteria
Mechanism
Type of Tumor ReferenceDirect Indirect
Clostridium Cluster IX Deoxycholic acid Liver cancer Yoshimoto et al., 2013
pks+ Escherichia coli PKS/ Colibactin Colorectal cancer Arthur et al., 2012
Dysbiosis/Prevotellaceae Immune response
CCL5
Colorectal cancer Elinav et al., 2011;
Hu et al., 2013;
Sobhani et al., 2011
Enterotoxigenic Bacteroides fragillis Immune response
Th17
Spermine oxidase
Colorectal cancer Wu et al., 2009
Goodwin et al., 2011
Commensal bacteria Immune response
IL-23 and IL-17
Colorectal cancer Grivennikov et al., 2012
Fusobacterium nucleatum Virulenc factor FadA Immune response
NF-kB, IL-6, IL-8, IL-18
Colorectal cancer Rubinstein et al., 2013;
Kostic et al., 2013exogenous triggers (Henao-Mejia et al., 2012). They represent
the sensory component of a multiprotein complex called the in-
flammasome. Once formed, mature inflammasomes recruit and
activate caspase enzymes that mediate the activation of the
cytokines IL-1b and IL-18 (Henao-Mejia et al., 2012). Recent
data show that control of the intestinal microbiota by the inflam-
masome is a central means of protecting gut homeostasis (Elinav
et al., 2011). The inflammasome component NLRP6 was shown
to have a protective role against the development of colitis-asso-
ciated cancer viamodulation of gutmicrobiota (Chen et al., 2011;
Normand et al., 2011). Intense inflammatory responses and
defective production of IL-18 were noted in the intestine in the
absence of NLRP6 (Elinav et al., 2011) (Chen et al., 2011). Addi-
tionally, it was shown that NLRP6 defends the host against
proliferation of certain bacteria (Anand et al., 2011; Anand and
Kanneganti, 2013).
These data together suggest that NLRP6 plays an important
role in regulating the gut microbiota communities by sensing
and controlling potentially pathogenic species. In support of
this notion, our group has shown that mice with perturbations
in the NLRP6 inflammasome pathway develop an altered micro-
biota with overrepresentation of several bacterial taxa, including
Prevotellaceae and TM7 (Elinav et al., 2011). This dysbiosis
caused spontaneous intestinal inflammation and increased sus-
ceptibility to colitis (Elinav et al., 2011). Furthermore, the dysbio-
sis associatedwith NLRP6 inflammasome deficiencywas able to
promote colorectal carcinogenesis. Mechanistically, the dysbio-
sis promoted inflammation via the chemokine CCL5, which re-
cruits a nonphysiological number of lymphocyte in the intestine.
The resulting inflammatory state promotes epithelial cell prolifer-
ation through local activation of the IL-6 pathway (Elinav et al.,
2011; Hu et al., 2013) (Figure 2). Interestingly, the dysbiotic
microbiota is fully transferable to wild-type mice horizontally
upon cohousing or vertically by cross-fostering. Whether the
transmitted Prevotellaceae and TM7 have direct protumorigenic
activity is not yet clear. Importantly, however, the dysbiotic
microbiota in the NLRP6-deficient mice are competitively domi-
nant over the endogenous microbiota and induce a stage of
inflammation following prolonged cohabitation with wild-type
mice (Elinav et al., 2011; Hu et al., 2013). These experiments
demonstrate that enhanced susceptibility to colon cancer inthis model is infectious and point to this dysbiotic microbiota
as a driving force of cancer. In line with this, intestinal dysbiosis
in mice deficient in Nod2, another NLR family member, was
reported to promote transmissible inflammation-induced colo-
rectal cancer (Couturier-Maillard et al., 2013). The molecular
inputs by which the host modulates the microbiota and the
cues by which representatives of the microbiota exert their
effects on the host remain to be studied.
Interestingly, bacteria of the Prevotellaceae family are also
found to be expanded in the fecal content of some patients
with colorectal cancer as compared to control subjects (Sobhani
et al., 2011), suggesting that the Prevotellaceae may contain
certain pathogenic bacterial species that promote inflamma-
tion-associated intestinal carcinogenesis.
Other studies focused on different components of the inflam-
masome, such as Nlrp3, Capase-1, and IL-18, support the role of
this complex in maintaining homeostasis in the intestine and in
suppressing tumor development in an indirect manner (Hu
et al., 2010, 2013; Allen et al., 2010; Henao-Mejia et al., 2012;
Zaki et al., 2010). Nlrp3- and Caspase-1-deficient mice develop
enhanced chronic colitis and colon rectal cancer in a mouse
model of colitis-associated inflammation-induced colorectal
cancer (Allen et al., 2010; Zaki et al., 2010). Likewise, Il18- and
Il18r-deficient mice were shown to be hypersusceptible to
DSS-induced colitis and colorectal tumorigenesis (Salcedo
et al., 2010). Moreover, administration of exogenous IL-18 allevi-
ated the severity of colitis and colitis-induced tumorigenesis in
Caspase1/11- and Nlrp3-deficient mice (Zaki et al., 2010).
Il1r-deficient mice showed a similar tumor load in the AOM/
DSS-induced colon rectal cancer model to that of WT mice.
These differences in phenotypes between altered states of IL-
1b or IL-18 signaling highlight the unique functions of these
two cytokines during intestinal tumor development and progres-
sion. As such, preferential inflammasome activation of either IL-
1b or IL-18, or their combined signaling, may lead to different
downstream physiological and pathophysiological conse-
quences. Differential activation of inflammasomes by microbiota
or host-derived factors may contribute to or even drive net in-
flammasome-induced effector function. Thus, context-specific
integrative inflammasome signaling in different cells and time
points may induce differences in the inflammasome-activatedCell 157, May 8, 2014 ª2014 Elsevier Inc. 777
Figure 1. The Immune System, Microbiota, and Tumors Are Tightly
Connected
The bacteria in the intestine can modulate tumor development through mul-
tiple different mechanisms that can be mainly divided into direct and indirect.
The direct mechanisms (blue line) are those in which microbial products
directly promote tumor growth. Of note, it has been shown that some de-
ficiencies in the immune system can allow the growth of certain procarcino-
genic bacteria. The indirect mechanisms (red line) are those in which the
bacteria per se are not able to promote tumor initiation and growth unless they
interact with the immune system, which ultimately promotes cancer. Finally, it
is also possible that deficiencies in specific mechanisms of the immune
response allow the expansion of certain bacteria, which, in turn, activate a
protumorigenic immune response (blue + red line).cytokine profile, resulting in differential downstream pheno-
types. These cell- and tissue-specific interplays between dif-
ferent inflammasomes at different stages of tumor formation
and growth will be exciting to characterize.
Taken together, these studies support the pivotal role of the in-
flammasome in regulating gut homeostasis and tumor develop-
ment. However, it still remains to be proven that an altered
microbiota is responsible for the phenotype observed in these
knock out mouse models.
Toll-like Receptors
TLRs recognize a variety of conserved pathogen-associated
molecular patterns (PAMPs) and endogenous stress signals
(Medzhitov, 2001; Palm and Medzhitov, 2009). Recognition of
the various microbial PAMPs by their cognate TLRs can activate
downstream signaling pathways, such as NF-kB, which leads to
the production of proinflammatory cytokines and chemokines
and enhances tumor cell proliferation and survival (Rakoff-
Nahoum and Medzhitov, 2009). Supporting this notion,
administration of TLR agonists such as lipopolysaccaride (LPS)
increases inflammation in the tumor microenvironment (Rakoff-
Nahoum and Medzhitov, 2009). Accordingly, deficiency in the
TLR-signaling adaptor molecule MyD88 and in one of the com-
ponents of the TLR family, TLR4, was found to be protective in
different mouse models of colon cancer (Rakoff-Nahoum and
Medzhitov, 2009). These results provided the first clue that the
TLR-mediated innate immune sensing of themicrobiota in the in-
testine is important in the regulation of tumorigenesis (Rakoff-
Nahoum and Medzhitov, 2009). Furthermore, genetic deficiency
of TLR causes alteration of the microbiota composition (Jin and
Flavell, 2013) and thereby might promote the outgrowth of
certain bacteria species with pathogenic potential. Alteration of778 Cell 157, May 8, 2014 ª2014 Elsevier Inc.gut microbiota may promote inflammation through enhanced
PAMP presentation to intestinal immune cells. For example,
mice lacking TLR2 or TLR5 have been shown to develop an
altered gut microbiota, which can cause spontaneous intestinal
inflammation and increased LPS in circulation. This has been
associated with the development of metabolic syndrome
featuring insulin resistance and obesity (Hu et al., 2013; Jiang
et al., 2013; Jin and Flavell, 2013; Wu et al., 2013). Given the
close association between inflammation and colorectal cancer,
it is conceivable that the colitogenic flora in these TLR2/TLR5-
deficient mice may also enhance intestinal tumorigenesis.
Finally, increased penetration of commensal flora into the tumor
as a result of diminished intestinal integrity in a mouse model of
colorectal tumorigenesis has also been shown to sustain tumor
growth through the activation of TLRs (Grivennikov et al.,
2012). In particular, bacterial components such as flagellin
bind to TLR5 and promote the release of the proinflammatory
cytokine IL-23 (Kinnebrew et al., 2012), which is highly ex-
pressed in both mouse and human intestinal tumors (Grivenni-
kov et al., 2012). When IL-23 is constitutively released at a high
level, it promotes a state of chronic inflammation, which can
abet the growth of the tumors (Grivennikov et al., 2012; Figure 3).
Microbially Influenced Adaptive Immune Response
Affecting Tumor Development
The adaptive arm of the host immune system is comprised
of cells that respond selectively and specifically to infectious
agents that the innate cells have collected and presented to
them. Some of these responses can be protumorigenic. For
example, upon contact with specific bacteria, CD4+ T cells can
produce protumorigenic cytokines. The following paragraphs
describe how certain members of the microbiota alter the adap-
tive immune response and, in turn, promote tumor growth.
Finally, we describe two examples of how the adaptive immune
system can keep its protumorigenic features in check.
Th17 Cells and Protumorigenic Cytokines
CD4+ T cells that express RORgt and, consequently, secrete
large amounts of IL-17 are called Th17 cells. The presence of
Th17 cells in the intestine is essential to control microbial inva-
sion, but specific compensatory mechanisms are required to
control Th17 cells. If those mechanisms fail, Th17 cells become
pathogenic and can induce chronic inflammation and autoim-
mune disease. A growing body of evidence suggests that Th17
cells and their cytokines also have a strong protumorigenic
potential in the intestine. Considering the capacity of certain
components of the microflora to modulate Th17 cell biology
(see below), we propose that this cell type is one of the main in-
struments by which the microbiota can indirectly promote tumor
growth.
IL-17A expression has been observed in several tumors and
appears to have pro- and antitumorigenic activities depending
on the type of tumor (Grivennikov et al., 2012; Muranski et al.,
2008). In the intestine, several lines of evidence support the
concept that IL-17A favors the development of colorectal
cancer. Mice that are genetically predisposed to develop tumors
in the intestine (APCmin/+) show a drastic impairment in intestinal
tumorigenesis when crossed with IL-17A-deficient mice (Chae
et al., 2010). Additionally, it has been shown that APCmin/+
Figure 2. Dysbiosis Associated with Inflammasome Deficiency Can Drive Inflammation-Induced Colorectal Cancer
The altered elements in the microbiota induce local colonic inflammation through epithelial reprogramming and induction of CCL5 transcription. This, in turn,
results in local induction of IL-6 secretion and resultant proliferative signaling on intestinal epithelial cells, culminating in tumor formation.mice that cannot respond to IL-17 develop fewer tumors in the
colon (Grivennikov et al., 2012).
Th17 cells produce other cytokines besides IL-17, such as
IL-22. IL-22 is a cytokine of the IL-10 family, which has been
linked to intestinal tumorigenesis in murine studies (Kirchberger
et al., 2013; Huber et al., 2012b). In addition, studies have linked
IL-22 to human colon cancer (Jiang et al., 2013) and, in partic-
ular, a chemo-resistant state of colorectal cancer (Wu et al.,
2013).
Myeloid cells produce the cytokine IL-23 in response to mole-
cules from the microbiota, such as flagellin (Kinnebrew et al.,
2012). This, in turn, promotes the expression of the cytokines
discussed above—IL-17A and IL-22—by Th17 cells (Huber
et al., 2012a). IL-23 is highly expressed in human colon cancer
samples compared to adjacent normal tissue (Grivennikov
et al., 2012; Langowski et al., 2006). It should be noted also
that innate lymphoid cells 3 (ILC3) are an important innate source
of IL-17 and IL-22 and a target of IL-23 (Figure 4) (Walker et al.,
2013). Accordingly, it has been recently shown that ILC3 can
sustain colon cancer through the production of IL-22 (Kirch-
berger et al., 2013).
Importantly, germ-free mice lack Th17 cells, suggesting that
endogenous microbiota are critical for the induction of this
type of cell. It has been shown that commensal bacteria can pro-
duce and release adenosine 50-triphospahate (ATP), which by
stimulating lamina propria dendritic cells (DC) to produce IL-6,
TGF-b, and IL-23, induces Th17 cell development (Atarashi
et al., 2008). Strikingly, the colonization of germ-free mice with
a specific member of commensal microbiota, the segmented
filamentous bacteria (SFB), promotes the induction of Th17 cells
(Ivanov and Honda, 2012). The presence of SFB in the small in-
testine promotes the induction/expansion of Th17 cells via their
stimulation of production of serum amyloid A, which, in turn,
promotes the differentiation of Th17 cells (Ivanov et al., 2009).
However, whether SFB can promote tumor growth through
Th17 cells remains to be evaluated.
More direct evidence for a role of bacterially stimulated
tumor growth via Th17 cells comes from studies of enterotoxi-
genic Bacteroides fragilis. This bacterium secretes B. fragilis
toxin (BFT) and causes human inflammatory diarrhea. Mice
that are predisposed to develop tumors in the intestine, when
colonized with this specific subgroup of B. fragilis, have a
remarkable Th17 cell tumor infiltration that results in an
increased tumor growth compared to noncolonized mice (Wu
et al., 2009).Overall these data support the role of Th17 cells and their
cytokines, IL-17 and IL-22, in intestinal carcinogenesis. If Th17
cells are overstimulated by a specific component of the micro-
biota, such as SFB and flagellin-positive bacteria, they can pro-
mote a state of chronic inflammation mediated by the release of
IL-17 and IL-22, which likely favors the development of intestinal
tumor growth (Figure 4).
An opposite and surprising microbiota-mediated effect was
recently noted with respect to the effect of the Th17 response
on a variety of solid and hematopoietic tumors. Interestingly,
this Th17 response was causally linked to microbial regulation
of chemotherapeutic treatment. Treatment with the alkylating
agent cyclophosphamide induced dysbiosis and enhanced in-
testinal penetration of Gram-positive commensal bacteria that
resulted in a potent tumor suppressive Th17 response (Viaud
et al., 2013). Likewise, a microbiota-mediated antitumorigenic
effect mediated through regulation of treatment was recently
noted in mice administered with an innate immune therapy con-
sisting of CpG oligodeoxyribonucleotides and anti-IL-10 recep-
tor antibodies, affecting tumor infiltrating myeloid cells (Iida
et al., 2013). In antibiotic-treated or germ-free mice, myeloid
cell response to this combined immunotherapy was impaired,
leading to enhanced tumor growth and establishing the micro-
biota as an important factor determining chemotherapeutic
responsiveness.
Tumor-suppressive Th17 cell subsets can therefore mediate
opposing chemotherapy-induced effects through alteration of
the gut microbiota, resulting in a net antitumorigenic response.
It is plausible that integration of such multiple signals through
their cumulative effects on specific commensal microbial popu-
lations and the various immune arms will result in context-spe-
cific effects on tumor growth, establishing the microbiota as a
critical hub integrating host and environmental signals partici-
pating in tumor formation or suppression.
Anti-Inflammatory Control Mechanisms
Th17 cells and their cytokine production can be kept in check by
regulatory T cells (Tregs) that produce the anti-inflammatory
cytokine IL-10 and dendritic cells that secrete IL-22-binding pro-
tein (IL-22BP). Thus, although some bacteria are able to induce
Th17 cells, we favor the idea that others could actually promote
control of Th17 cells and thereby limit carcinogenesis. For
example, Lactobacillus, Bifidobacteria, and Clostridium genera
induce a specific subset of regulatory T cells in the intestine
called Foxp3+ Treg cells (Honda and Littman, 2012). These
Foxp3+ Treg cells, through the secretion of IL-10, can controlCell 157, May 8, 2014 ª2014 Elsevier Inc. 779
Figure 3. Microbes, TLRs, and Tumorigenesis
Microbial PAMPs activate TLR signaling in a variety of cell types, leading to
cytokine production and NF-kB-mediated inflammation, which can fuel tumor
growth. These events can also alter the gut microbiota such that it can feed
back to TLR signaling augmenting inflammation.the production of IL-17A and the proliferation of Th17 cells
(Figure 4) (Huber et al., 2011). We hypothesize that these interac-
tions can have antitumorigenic activity in the intestine. In support
of this notion, it is known that Foxp3+ Treg cells can actively
block intestinal tumor growth through the production of IL-10
(Erdman et al., 2003; Erdman et al., 2005). Whether this is due
to the suppression of Th17 cell protumorigenic activity remains
to be determined.
Bacteroides fragilis releases polysaccharide A (PSA) and
blocks intestinal inflammation. IL-10 and type 1 regulatory T
(Tr1) cells, a distinct subset of regulatory T cells characterized
by the secretion of high concentration of IL-10 and surface
expression of CD49b and LAG-3, are required for this beneficial
effect (Mazmanian et al., 2008). Conversely, IL-10-deficient mice
develop chronic inflammation that is exacerbated when themice
are colonized by Helicobacter hepaticus. H. hepaticus not only
promotes inflammation in the colon, but is also associated with
a high incidence of tumor development in these mice (Fox
et al., 2011). However the hypothesis that Tr1 cells and their
secreted IL-10 can have antitumorigenic capacity via suppress-
ing Th17 cells remains to be tested. Of note,Bifidobacterium lon-
gum, one of the commensal bacteria in mice, induces moderate
levels of Tr1 cells, and feeding mice with Bifidobacterium breve,
which is normally not present in the intestine of mice, strongly
promotes the accumulation of Tr1 cells in the colon (Jeon
et al., 2012). Interestingly, cancer patients have a significantly
reduced population of Bifidobacterium longum compared to pa-
tients with inflammatory bowel disease (Gueimonde et al., 2007).780 Cell 157, May 8, 2014 ª2014 Elsevier Inc.Recently, a selected mixture of Clostridia strains was identi-
fied from the human microbiota that is able to attenuate disease
in preclinical models of colitis through the induction of IL-10+
regulatory T cells (Atarashi et al., 2013). These data may reveal
a potential antitumorigenic role of a certain component of the
microbiota and suggest that therapeutic colonization with spe-
cific strains of human-associated bacteria may have the poten-
tial to reduce tumorigenesis, but definitive preclinical and clinical
data are still missing.
DC present in the intestine continuously release a soluble IL-
22 receptor, IL-22-binding protein (IL-22BP, IL-22Ra2). IL-
22BP binds to IL-22 and limits its bioavailability by prohibiting
the binding of IL-22 to the membrane-bound IL-22 receptor
(IL-22R1). Mice that are deficient for IL-22BP show increased
IL-22-mediated tumorigenesis in colitis-associated and sponta-
neous colon cancer models. The integrity of the intestinal epithe-
lial cell barrier is required for high IL-22BP expression in the
intestine (Huber et al., 2012b). Conversely, tissue damage and
bacteria infiltration lead to downregulation of IL-22BP. This
mechanism is controlled by inflammasomes (NRLP3/6) that pro-
mote the release of IL-18, which, in turn, downregulates IL-22BP
expression by DC (Huber et al., 2012b). On the other hand, bac-
terial components can also stimulate DC to produce IL-23 (Kin-
nebrew et al., 2012), which induces IL-22 production by ILC3
(Huber et al., 2012a; Kirchberger et al., 2013). IL-22 then favors
wound healing and limits bacteria-driven inflammation (Hanash
et al., 2012; Sonnenberg et al., 2011). Of note, IL-22BP is re-ex-
pressed during the wound recovery phase, thereby dampening
the IL-22-induced regenerative program, which, if uncontrolled,
can promote tumor formation (Huber et al., 2012b) (Figure 4).
Alteration of the Human Intestinal Microbiota as a
Therapeutic Approach?
It is largely accepted that patients with chronic inflammation in
the intestine have a higher propensity to develop intestinal tu-
mors. The data reviewed here suggest that chronic inflammation
in the intestine could be, at times, the result of a pathogenic inter-
action of themicrobiota withmultiple components of the immune
system. We also interpret the data reviewed in the previous sec-
tion to indicate that the microbiota can be leveraged to limit
inflammation and thereby mitigate cancer risk. Thus, the possi-
bility of retraining tumor progression by controlling intestinal
microbiota in patients seems logical to envision. Below, we high-
light evidence that the human microbiota can be therapeutically
manipulated to control intestinal inflammation. However, an
effect on tumor development has not been established.
Strategies to manipulate the microbiota therapeutically
include oral administration of certain bacteria strains (‘‘probiot-
ics’’), dietary interventions to alter microbiota composition
(‘‘prebiotics’’), and fecal transplantation. Examples of such inter-
ventions include the administration of Escherichia coli Nissle
1917, a bacterium that was isolated from the stool of a World
War I soldier who, in contrast to his comrades, did not suffer
from diarrhea. This bacterium was suggested to be an efficient
therapy in patients suffering from ulcerative colitis (Kruis et al.,
2004). Dietary interventions have been shown to be efficient
in reducing the inflammatory response in the IL-10-deficient
mice, which spontaneously develops colitis (Devkota et al.,
Figure 4. Interplay between Microbes,
Proinflammatory, and Anti-Inflammatory
Immune Cells and Cytokines that May Influ-
ence Tumor Growth
Upon tissue damage and bacterial invasion,
NLRP3/NLRP6 activate IL-18, which down-
regulates IL-22BP production by intestinal DC.
Moreover, when DC sense bacterial components
via TLR5, they produce IL-23. This cytokine acts
on ILCs and, together with IL1b on Th17 cells,
promotes the production of IL-17A and IL-22.
Adequate levels of these two cytokine promote
antimicrobial peptide secretion and tissue regen-
eration; their levels are kept in check by IL-22BP
and IL-10 from regulatory T cells, which, in turn,
may be induced by specific commensal bacteria.
If IL-17A and IL-22 are not controlled, they can
promote tumorigenesis.2012). Finally, fecal transplantation showed efficacy in treating
patients suffering from chronic Clostridium difficile infection
(van Nood et al., 2013). Similar approaches are currently being
tested in patients with inflammatory bowel disease. However,
the results of the first small studies are conflicting: whereas fecal
transplantation was shown to be efficient in children and young
adults with ulcerative colitis (Kunde et al., 2013), another study
did not show efficacy in patients with chronic active ulcerative
colitis (Kump et al., 2013). Larger studies will be essential to
clarify this point.
Concluding Remarks and Future Perspectives
The immune system is able to trigger and sustain tumor cell
growth. The microbiota shapes the immune system and thereby
can indirectly modulate the development of tumors through the
immune system. We believe that developing methods to selec-
tively manipulate components of the microbiota and ultimately
target tumor initiation and progression represents a complex
yet exciting challenge in the field. Although the intestinal micro-
biota is mainly localized to the gut and was originally suggested
to display regulatory functions within the intestinal mucosa,
recent evidence indicates that functional microbiota alterations
may also have systemic effects impacting other parts of the
body (Henao-Mejia et al., 2012). As such, we hypothesize that
the microbiota and its interactions with the host could also be
important in tumorigenesis in other organs. This approach re-
quires first the identification of the relevant bacteria in humans,
their altered interactions with the human immune system, and
their ultimate effects on tumor initiation and progression. Sec-
ond, we need to identify methods to selectively manipulate the
microbiota. Such modalities could represent novel therapeutic
interventions to be coupled with conventional treatments for
the therapy of tumors and other multifactorial human diseases.
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